It is worth noting that B-cell maturation antigen (BCMA) is a transmembrane glycoprotein in TNFRSF17, and current targeted immunotherapy for BCMA has been used in clinical trials of multiple myeloma with satisfactory results (29–31). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.